Study of BHV-1300 in Graves' Disease

Launched by BIOHAVEN THERAPEUTICS LTD. · May 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called BHV-1300 for people with Graves' Disease, a condition that causes the thyroid gland to become overactive, leading to symptoms like anxiety, weight loss, and increased heart rate. The main goal of the study is to see if BHV-1300 is safe and effective for treating this condition. The trial is not yet recruiting participants, but it will include adults aged 18 to 75 who have a confirmed diagnosis of Graves' Disease and are currently experiencing symptoms related to hyperthyroidism.

To be eligible for this study, participants must have a specific type of overactive thyroid caused by Graves' Disease. However, individuals with other causes of hyperthyroidism or those who have recently undergone certain treatments, like radioactive iodine therapy or thyroid surgery, will not be able to participate. If you join this study, you can expect to undergo various assessments to monitor your health and the effects of the treatment. Your safety and well-being will be a priority throughout the trial.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • 1. Participants must have serologically confirmed Graves' Disease.
• • 2. Participants must have active hyperthyroidism due to Graves' Disease.
• Key Exclusion Criteria:
• • 1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
• • 2. History of treatment with radioactive iodine or thyroid surgery.